Trials / Completed
CompletedNCT00143208
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom (Fixed Combination Of Latanoprost And Timolol) In Patients With Poag Or Oh. A 6-Month, Open, Multi-Center Trial In Italy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 250 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination (Xalacom) after 6 month of treatment. Eligible patients may be enrolled at the baseline visit. All current ocular hypotensive therapy must be discontinued at this time. On baseline day, patients eligible for the study will receive Xalacom which is to be instilled in the morning.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xalacom |
Timeline
- Start date
- 2003-05-01
- Completion
- 2006-04-01
- First posted
- 2005-09-02
- Last updated
- 2021-02-21
Locations
21 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00143208. Inclusion in this directory is not an endorsement.